[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100525537":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":25,"centralContacts":25,"locations":29,"responsibleParty":50,"collaborators":25,"id":52,"slug":53,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":25,"eligibilityCriteria":58,"healthyVolunteers":59,"sex":60,"minAge":61,"maxAge":62,"enrollmentInfo":63,"targetDuration":25,"studyType":66,"phases":67,"briefSummary":69,"conditions":70,"keywords":25,"overallStatus":32,"whyStopped":25,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"Northwestern University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Cabergoline","EXPERIMENTAL","1mg oral cabergoline administered once after patient's procedure",[13],"Drug: Cabergoline",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","1 tablet encapsulated placebo by Investigational Drug Pharmacy administered once after patient's procedure",[19],"Drug: Placebo",[21,26],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","1mg oral cabergoline given to participants once",[9],null,{"type":22,"name":15,"description":27,"armGroupLabels":28,"otherNames":25},"1 encapsulated placebo tablet given to participants after procedure",[15],[30],{"facility":31,"status":32,"city":33,"state":34,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"Northwestern Medical Center","RECRUITING","Chicago","Illinois","60611","United States","US",{"type":39,"coordinates":40},"Point",[41,42],-87.65005,41.85003,{"lat":42,"lon":41},[45],{"name":46,"role":47,"phone":48,"phoneExt":25,"email":49},"Leanne McCloskey","CONTACT","312-926-8678","erin.fleurant@nm.org",{"type":51,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100525537","phase-4-pharmacological-inhibition-of-lactation-after-16-to-20-week-abortion-100525537",false,"NCT06123026","Pharmacological Inhibition of Lactation After 16 to 20 Week Abortion","Pharmacological Inhibition of Lactation After 16 to 20 Week Abortion: a Randomized Controlled Trial","Inclusion Criteria:\n\n* pregnant individuals seeking termination of pregnancy after 16w0d gestation and up to 19w6d gestation. this includes management of intrauterine demises\n* ages 18 to 50\n* con provide informed consent in English\n\nExclusion Criteria:\n\n* Age under 18 or above 50\n* gestational ages before 16 weeks 0 days or after 20 weeks 0 days\n* unable to provide written consent in English\n* hypertensive disorder\n* uncontrolled hypertension or known hypersensitivity to ergot derivatives\n* History of cardiac valvular disorders\n* history of pulmonary fibrosis\n* documented bipolar schizophrenia\n* documented allergy to medication, including lactose intolerance (placebo pill involves lactose)",true,"FEMALE","18 Years","50 Years",{"count":64,"type":65},200,"ESTIMATED","INTERVENTIONAL",[68],"PHASE4","The goal of this clinical trial is to compare breast symptoms (lactation, engorgement, etc) of individuals who undergo a procedure for second trimester of pregnancy loss between 16 weeks and 20 weeks gestational age. The participants will be randomly placed in two groups, one with a placebo tablet and one with medication called \"cabergoline\" which are taken immediately after their procedure. Researchers will compare groups to see if there are any significant differences in breast symptoms.",[71,72],"Lactation Suppressed","Second Trimester Abortion","2024-05-28",{"date":75,"type":76},"2024-05-29","ACTUAL",{"date":78,"type":76},"2023-12-18",{"date":80,"type":65},"2024-06-30",{"name":5,"class":6},1]